What is William Blair’s Estimate for MRSN Q1 Earnings?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Investment analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Mersana Therapeutics in a research report issued to clients and investors on Monday, March 3rd. William Blair analyst A. Hsieh expects that the company will post earnings of ($0.20) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. William Blair also issued estimates for Mersana Therapeutics’ Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.85) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.22) EPS and FY2027 earnings at ($0.89) EPS.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The company had revenue of $16.36 million during the quarter, compared to analysts’ expectations of $7.71 million.

A number of other equities analysts have also commented on MRSN. Wedbush reiterated an “outperform” rating and issued a $4.00 price objective on shares of Mersana Therapeutics in a research note on Monday. Citigroup initiated coverage on Mersana Therapeutics in a research note on Friday, November 15th. They issued a “buy” rating and a $5.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.25.

Mersana Therapeutics Trading Up 0.8 %

Mersana Therapeutics stock opened at $0.51 on Thursday. The company has a debt-to-equity ratio of 13.35, a quick ratio of 2.35 and a current ratio of 2.35. The business’s 50-day simple moving average is $0.79 and its 200-day simple moving average is $1.56. The firm has a market capitalization of $63.30 million, a PE ratio of -0.84 and a beta of 1.39. Mersana Therapeutics has a 52 week low of $0.46 and a 52 week high of $6.28.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MRSN. Novo Holdings A S acquired a new position in Mersana Therapeutics during the 4th quarter worth $6,078,000. Boxer Capital Management LLC bought a new stake in shares of Mersana Therapeutics during the 4th quarter valued at $3,768,000. Verition Fund Management LLC raised its position in shares of Mersana Therapeutics by 11,695.2% during the 3rd quarter. Verition Fund Management LLC now owns 1,303,249 shares of the company’s stock valued at $2,463,000 after acquiring an additional 1,292,200 shares during the last quarter. Exome Asset Management LLC bought a new stake in shares of Mersana Therapeutics during the 3rd quarter valued at $2,227,000. Finally, 683 Capital Management LLC raised its position in shares of Mersana Therapeutics by 392.4% during the 4th quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock valued at $1,287,000 after acquiring an additional 717,207 shares during the last quarter. Institutional investors and hedge funds own 93.92% of the company’s stock.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.